Mural Oncology plc (NASDAQ: MURA)’s stock price has gone decline by -5.84 in comparison to its previous close of 4.11, however, the company has experienced a 5.74% increase in its stock price over the last five trading days. globenewswire.com reported 2025-03-11 that Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025
Is It Worth Investing in Mural Oncology plc (NASDAQ: MURA) Right Now?
The stock has a 36-month beta value of 2.42. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MURA is 15.34M, and at present, short sellers hold a 2.32% of that float. On March 21, 2025, the average trading volume of MURA was 159.25K shares.
MURA’s Market Performance
MURA’s stock has seen a 5.74% increase for the week, with a -9.37% drop in the past month and a 12.50% gain in the past quarter. The volatility ratio for the week is 8.76%, and the volatility levels for the past 30 days are at 6.68% for Mural Oncology plc The simple moving average for the past 20 days is 2.80% for MURA’s stock, with a 10.48% simple moving average for the past 200 days.
Analysts’ Opinion of MURA
Many brokerage firms have already submitted their reports for MURA stocks, with Rodman & Renshaw repeating the rating for MURA by listing it as a “Buy.” The predicted price for MURA in the upcoming period, according to Rodman & Renshaw is $15 based on the research report published on June 28, 2024 of the previous year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see MURA reach a price target of $13. The rating they have provided for MURA stocks is “Overweight” according to the report published on April 04th, 2024.
MURA Trading at -0.48% from the 50-Day Moving Average
After a stumble in the market that brought MURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.41% of loss for the given period.
Volatility was left at 6.68%, however, over the last 30 days, the volatility rate increased by 8.76%, as shares sank -8.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.50% upper at present.
During the last 5 trading sessions, MURA rose by +5.74%, which changed the moving average for the period of 200-days by +15.18% in comparison to the 20-day moving average, which settled at $3.76. In addition, Mural Oncology plc saw 20.19% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MURA starting from Loew Caroline, who proposed sale 4,313 shares at the price of $3.36 back on Mar 04 ’25. After this action, Loew Caroline now owns shares of Mural Oncology plc, valued at $14,491 using the latest closing price.
Keson-Brookes Maiken, the of Mural Oncology plc, sale 1,469 shares at $3.45 during a trade that took place back on Mar 05 ’25, which means that Keson-Brookes Maiken is holding 73,564 shares at $5,068 based on the most recent closing price.
Stock Fundamentals for MURA
The total capital return value is set at -0.97. Equity return is now at value -183.89, with -131.73 for asset returns.
Based on Mural Oncology plc (MURA), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -16.02.
The liquidity ratio also appears to be rather interesting for investors as it stands at 7.38.
Conclusion
To sum up, Mural Oncology plc (MURA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
